TRIM35 inhibitors belong to a class of chemical compounds designed to target and modulate the activity of the TRIM35 protein, which stands for Tripartite Motif Containing 35. TRIM35 is a member of the tripartite motif (TRIM) protein family, which includes a diverse group of proteins involved in various cellular processes, such as immune response regulation, antiviral defense, and protein degradation. While the precise function of TRIM35 is still the subject of ongoing research, it is known to contain structural motifs characteristic of E3 ubiquitin ligases, which are enzymes involved in the post-translational modification of proteins with ubiquitin, marking them for degradation or altering their functions. Inhibitors of TRIM35 are developed to interfere with its enzymatic activity or other functions, potentially influencing protein ubiquitination and other cellular processes governed by this protein.
The mechanisms by which TRIM35 inhibitors function can vary based on their chemical structures and binding properties. Some inhibitors may directly interact with TRIM35, preventing its E3 ubiquitin ligase activity or disrupting its interactions with target proteins. Others may modulate the stability or conformation of TRIM35, affecting its ability to mediate ubiquitination events or other functions. By inhibiting TRIM35, these compounds have the potential to impact protein ubiquitination, protein turnover, or cellular processes regulated by this protein, which may include immune signaling pathways or antiviral responses. Ongoing research in this field aims to elucidate the precise mechanisms and downstream effects of TRIM35 inhibition, contributing to our understanding of its role in cellular biology and its significance in various cellular processes.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Methotrexate | 59-05-2 | sc-3507 sc-3507A | 100 mg 500 mg | $92.00 $209.00 | 33 | |
A folate analog that inhibits dihydrofolate reductase, leading to reduced purine synthesis and potentially affecting gene expression. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
A nucleoside analog of cytidine that can be incorporated into RNA and DNA and may lead to hypomethylation of DNA. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $130.00 $270.00 | 37 | |
A histone deacetylase inhibitor which can lead to a more relaxed chromatin state, potentially modifying gene expression. | ||||||
Mithramycin A | 18378-89-7 | sc-200909 | 1 mg | $54.00 | 6 | |
A compound that binds to G-C rich sequences in DNA, potentially altering transcription factor access to genes. | ||||||
Pioglitazone | 111025-46-8 | sc-202289 sc-202289A | 1 mg 5 mg | $54.00 $123.00 | 13 | |
A peroxisome proliferator-activated receptor gamma (PPARγ) agonist that regulates gene expression involved in metabolism. | ||||||
Olaparib | 763113-22-0 | sc-302017 sc-302017A sc-302017B | 250 mg 500 mg 1 g | $206.00 $299.00 $485.00 | 10 | |
A PARP inhibitor which may affect DNA repair processes and thereby influence expression of various genes including TRIM35. | ||||||
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $57.00 $182.00 $92.00 | 21 | |
An inhibitor of Topoisomerase I, which could lead to altered gene expression due to changes in DNA topology. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor which can affect protein synthesis and has broad effects on cellular growth and gene expression. | ||||||
Fluorouracil | 51-21-8 | sc-29060 sc-29060A | 1 g 5 g | $36.00 $149.00 | 11 | |
A compound that is metabolized to nucleotide analogs which can be incorporated into RNA and DNA, affecting gene expression. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $254.00 | 41 | |
A cyclin-dependent kinase inhibitor which may alter cell cycle progression and gene expression profiles. | ||||||